Congratulations to Taimei Medical Technology on its successful listing on the Hong Kong Stock Exchange! | 5Y News
Empowering the global pharmaceutical R&D industry.
On October 8, 2024, Zhejiang Taimei Medical Technology Co., Ltd. ("Taimei Medical Technology," stock code: 02576.HK) announced its official listing on the Main Board of the Hong Kong Stock Exchange.
At the listing ceremony, Zhao Lu, Chairman, Executive Director, and General Manager of Taimei Medical Technology, and Ni Xiaomei, Executive Director, General Counsel, and Board Secretary, jointly struck the opening gong to celebrate the company's embarkation on a new journey. Members of the board of directors, board of supervisors, and senior management, shareholder representatives, as well as sponsors and intermediaries for this IPO, attended the ceremony to witness this milestone moment in the company's development.
In his speech, Zhao Lu stated: "Successfully entering the Hong Kong capital market marks a brand-new starting point for Taimei Medical Technology's growth. With the strength of the capital market behind us, Taimei Medical Technology will remain committed to our founding mission of 'unleashing the power of digitalization to make health accessible,' continuously innovating our products and services, improving operational quality and efficiency, contributing to the development and accessibility of more quality drugs and medical devices, enabling more patients to embrace health, and in doing so, repaying the support and trust of our investors."
5Y Capital participated in three consecutive funding rounds for Taimei between 2018 and 2020. Jing Xu, Managing Director at 5Y Capital, commented: "Congratulations to Taimei on its IPO at the Hong Kong Stock Exchange. This represents a new beginning for the company and will enable it to better empower the global pharmaceutical R&D industry. China possesses the world's richest clinical research resources. As global demand for new drug development continues, the total volume of clinical research conducted in China will keep rising, and the standards for process management, data quality, and research efficiency will only become more demanding. Therefore, the industry's need for informatization, efficiency tools, and collaboration applications has become irreversible. As a leading player in the sector, Taimei has been continuously improving its informatization and collaboration 'infrastructure,' while the various stakeholders in clinical research that have already gathered on its platform have developed stable habits of efficiency improvement and collaboration. We believe that as more clients join and Taimei continues to provide more diverse and efficient services, the efficiency of new drug development in China and globally will see substantial further improvement."
Taimei Medical Technology IPO ceremony
As a digital solutions provider focused on the pharmaceutical and medical device industries, Taimei Medical Technology has been dedicated to leveraging advanced digital and intelligent technologies to advance these industries and benefit patients worldwide since its founding in 2013. As of March 31, 2024, the company offers industry participants over 40 software products and digital services, covering trial design and management, patient recruitment and follow-up, data collection and analysis, and other scenarios, meeting the diverse needs of different organizations and roles.
To address industry collaboration challenges, the company has innovatively developed two digital collaboration platforms — TrialOS and PharmaOS — effectively connecting hospitals, pharmaceutical companies, third-party service providers, patients, and regulatory agencies across the industry ecosystem. These platforms establish unified standards, enable data flow, facilitate process collaboration, and integrate resources, supporting the industry's digital and intelligent transformation, enhancing overall R&D efficiency for pharmaceuticals and medical devices as well as post-market commercial performance, and creating shared value for all parties.
As of March 31, 2024, Taimei Medical Technology has served over 1,400 pharmaceutical companies and CROs, covering 21 of the world's top 25 pharmaceutical companies and 90 of China's Top 100 Pharmaceutical Innovators. The company has also established partnerships with over 700 national drug clinical trial institutions, of which more than 80% are Class III Grade A hospitals. By customer count, the company has become the most widely adopted digital solutions provider in pharmaceutical and medical device R&D and marketing in China.
5Y Capital seeks out, supports, and inspires lone entrepreneurs, providing them with support ranging from spiritual encouragement to all aspects of business operations. We believe that if the world begins to believe in the "crazy" you that others see, the world will become a different place.
BEIJING · SHANGHAI · SHENZHEN · HONG KONG
